InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company , has announced that the first patient has been dosed in a Phase Ib clinical study. The study is evaluating the combination of InnoCare’s SHP2 allosteric inhibitor, ICP-189, with the selective EGFR inhibitor furmonertinib for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
Furmonertinib, originally discovered by Allist Pharmaceuticals based in China, is being supplied for the trial by ArriVent Biopharma Inc., a U.S. biotech company listed on Nasdaq (Nasdaq: AVBP). This collaboration between InnoCare and ArriVent was first announced in July 2023 and aims to leverage the potential synergies of the two drugs in treating NSCLC.
Allist Pharmaceuticals has already obtained approval in China for furmonertinib as a first-line treatment for adults with locally advanced or metastatic NSCLC that harbors EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations. The drug is also under global development for NSCLC with EGFR mutations, including exon 20 insertion mutations.
ICP-189, developed by InnoCare, is a potent and selective oral allosteric inhibitor of SHP2, intended for the treatment of solid tumors, either as a monotherapy or in combination with other antitumor agents.- Flcube.com
